Franciscus Gasthuis & Vlietland
Rotterdam, South Holland, 3045PM, Netherlands
NCT Number: NCT06677242
Background: Serous endometrial intra-epithelial carcinoma (SEIC) is a rare condition affecting the lining of the uterus. It's a pre-cancerous change that might lead to cancer if not treated. Doctors aren't sure of the best way to manage it because it's so uncommon. A previous study looked at past cases in the Netherlands from 2012 to 2020. This study found that none of the 23 women with SEIC had their cancer spread during surgery, and none had a recurrence in the following three years. This suggests that a simpler surgery might be safe for patients with SEIC.
Methods: Information on disease details from patients who agree to participate in our study will be collected. All participants will fill out online forms and health questionnaires at several points: when they join the study, and again at six months, two years, and five years after their diagnosis. During the years after diagnosis, various details like health status, test results, treatments will be checked in the electronic medical record.
Results: This study is just starting, with the first patients expected to join on January 1, 2025.
Conclusion: A large international study is created to track SEIC patients over time. This will help us learn more about the condition and improve treatment strategies.
Trial opening soon.
Get Notified18 year and older
Female
Observational
Rotterdam, South Holland, 3045PM, Netherlands
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
These are additional tests, added to the observational study to collect information on tumor characteristics and to pursue early detection of this diagnosis.
Time frame: 5 years
Survival without recurrence of endometrial neoplasm
Time frame: 5 years
Time frame: 5 years
Assessed through EORTC questionnaires Assessed through three different questionnaires: EORTC-QLQ-C30 + QLQ-EN24 (together a total of 54 multiple-choice questions with a scale of 1-4 of severity of complaints) and EQ-5D-5L (multiple-choice, scale of severity, all different items will be entered in the digital database)
Time frame: 5 years
Any adverse event related to the treatment of SEIC
Contact information is provided by the study sponsor or research team.
Erasmus Medical Center
Other
Acronym: SEIC
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07738315
Endometrial Carcinoma, Endometrial Neoplasms
Hangzhou, Zhejiang, China
View Trial DetailsNCT07739745
Endometrial Cancer, Endometrial Neoplasms
Houston, Texas, United States
View Trial DetailsNCT07737795
Endometrial Cancer, Endometrial Neoplasms
Oklahoma City, Oklahoma, United States
View Trial DetailsNCT07731607
Endometrial Neoplasms, Female Urogenital Diseases
View Trial Details